Active ingredients: gemcitabine
What it is used for
Gemcitabine DRLA is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,Gemcitabine DRLA is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ,Gemcitabine DRLA is also indicated for patients with 5-FU refractory pancreatic cancer. ,Gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,Gemcitabine DRLA in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,Gemcitabine DRLA in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinumbased therapy.
How to take it
The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
- Store below 25 degrees Celsius
- Do not Refrigerate
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
White to off white lyophilized powder
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient gemcitabine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems